These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 27777009)
1. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold. Wang M; Xu S; Lei H; Wang C; Xiao Z; Jia S; Zhi J; Zheng P; Zhu W Bioorg Med Chem; 2017 Oct; 25(20):5754-5763. PubMed ID: 28927801 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit. Wu C; Wang M; Tang Q; Luo R; Chen L; Zheng P; Zhu W Molecules; 2015 Oct; 20(10):19361-71. PubMed ID: 26512636 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, activity and docking studies of phenylpyrimidine-carboxamide Sorafenib derivatives. Wang W; Wu C; Wang J; Luo R; Wang C; Liu X; Li J; Zhu W; Zheng P Bioorg Med Chem; 2016 Dec; 24(23):6166-6173. PubMed ID: 28340913 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides. Wang M; Wu C; Xu S; Zhu Y; Li W; Zheng P; Zhu W Med Chem; 2017; 13(2):176-185. PubMed ID: 27855595 [TBL] [Abstract][Full Text] [Related]
6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents. Yao J; He Z; Chen J; Sun W; Fang H; Xu W Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib. Lu CS; Tang K; Li Y; Jin B; Yin DL; Ma C; Chen XG; Huang HH Yao Xue Xue Bao; 2013 May; 48(5):709-17. PubMed ID: 23888694 [TBL] [Abstract][Full Text] [Related]
12. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety]. Qin AF; Li Y; Song HR; Chen XG; Jin XF; Wang K; Zhang LJ; Huo LC; Feng ZQ Yao Xue Xue Bao; 2012 Dec; 47(12):1623-9. PubMed ID: 23460968 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731 [TBL] [Abstract][Full Text] [Related]